- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01342757
Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma
Using Proton Magnetic Resonance Spectroscopy (MRS) to Predict Response of Vorinostat Treatment in Glioblastoma
Study Overview
Status
Detailed Description
PRIMARY OBJECTIVES:
I. To evaluate the strength of the association between magnetic resonance spectroscopy (MRS) imaging measurable biomarkers and response to vorinostat plus temozolomide.
SECONDARY OBJECTIVES:
I. To evaluate MRS-detected inositol and N-acetylaspartate (NAA) levels (at 3 tesla) as indicators of mood alterations as measured by a self-report depression survey (IDS-SR).
OUTLINE:
Patients receive vorinostat orally (PO) once daily (QD) on days -7 to -1 (course 1 only) and days 8-14 and 22-28 and temozolomide PO QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients previously treated with standard radiotherapy and temozolomide receive maintenance temozolomide PO on days 1-5.
Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicities. Patients undergo magnetic resonance spectroscopy imaging at baseline and at approximately 1 and 8 weeks on treatment. Patients also undergo an Inventory of Depression Symptomatology Self-Reported (IDS-SR) assessment at baseline and periodically during study.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients must have 1 of the following:
Diagnosis of recurrent or progressive glioblastoma
- Patients with recurrent disease may have had treatment for any number of prior relapses
- Newly diagnosed glioblastoma and have completed radiation therapy and are receiving standard follow-up temozolomide
- Must be able to have an MRI, and have a measurable contrast-enhancing supratentorial tumor of at least 1 cm by shortest diameter
- Residual disease following resection measuring 1 cm in diameter or greater is mandated for eligibility into the study
- Patients must have a stable or progressive disease as determined by serial brain MRI using the McDonald Criteria on a scan 14 days or fewer before registration and on a stable steroid dose for 5 days
- Patients with prior therapy that included interstitial brachytherapy or stereotactic radiosurgery must have confirmation of true progressive disease rather than radiation necrosis based upon either positron emission tomography (PET) or thallium scanning, MR spectroscopy, or surgical documentation of disease
- White Blood Cell Count > 3,000/μL
- Absolute Neutrophil Count > 1,500/μL
- Platelet count > 100,000/μL
- Hemoglobin > 10 g/dL (transfusion allowed)
- Serum glutamate oxaloacetate transaminase < 2 times upper limit of normal (ULN)
- Bilirubin < 2 times ULN
- Creatinine < 1.5 mg/dL
- Negative pregnancy test
- Women of childbearing potential and men must agree to use adequate barrier contraception for the duration of study participation
- Able to swallow capsules
- No patients with pacemakers, non-titanium aneurysm clips, neurostimulators, cochlear implants, non-titanium metal in ocular structures, history of being a steel worker, or other incompatible implants
- No significant medical illnesses that, in the investigator's opinion, cannot be adequately controlled with appropriate therapy or would compromise the patient's ability to tolerate this therapy
- No history of any other cancer except non-melanoma skin cancer or carcinoma in-situ of the cervix, or cancer in complete remission and off all therapy for ≥ 3 years
- No active infection or serious intercurrent medical illness
- No disease that would obscure toxicity or dangerously alter drug metabolism
- No history of allergic reactions attributed to compounds of similar chemical or biologic composition to vorinostat (SAHA) or other agents used in this study
- No prolonged corrected QT interval waves on baseline EKG
- No other anticancer therapy (including chemotherapy, radiation, hormonal treatment, or immunotherapy) of any kind is permitted during the study period
- At least 3 weeks since prior radiotherapy
- Patients must have recovered from the toxic effects of prior therapy, including surgery
- At least 28 days since any prior investigational agent or prior cytotoxic therapy
- At least 23 days since prior temozolomide
- At least 14 days since prior vincristine (42 days for nitrosourea)
- At least 21 days since prior procarbazine
- At least 7 days since prior non-cytotoxic agents (e.g., interferon, tamoxifen, thalidomide, cis-retinoic acid, etc.)
- At least 2 weeks since prior valproic acid (or another histone deacetylase inhibitor)
- No other concurrent investigational agents
Exclusion Criteria:
- Diagnostic and Statistical Manual-IV Axis I or II diagnosis (as determined by PI), exclusive of nicotine dependence.
- Pregnant.
- Contraindications to MRI: pacemaker, aneurysm clips, neurostimulators, cochlear implants, metal in eyes, steel worker, or other implants.
- Active medical or neurological disorder.
- History of alcohol or drug dependence
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm I
Patients receive vorinostat once daily on days -7 to -1 (course 1 only) and days 8-14 and 22-28 and temozolomide on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo magnetic resonance spectroscopic imaging at baseline and at approximately 1 and 8 weeks on treatment. Patients also undergo a survey administration of Inventory of Depression Symptomatology Self-Reported (IDS-SR) assessment at baseline and periodically during study. |
Given orally
Other Names:
Ancillary studies
Given orally
Other Names:
Undergo MRI
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of Patients With Magnetic Resonance Spectroscopy (MRS) Response to Initial Vorinostat by MRI and MRS Scans as Determined by Spectroscopic Index
Time Frame: 9 weeks
|
Changes in magnetic resonance spectroscopic imaging signal and semiquantitative analysis of inositol, choline, lactate, and N-acetylaspartate signal are measured.
The values for each of these metabolites are normalized to baseline at one and nine weeks.
The values of all the metabolites at one week are added and this is the magnetic resonance spectroscopic index for one week.
This is done again at nine weeks.
The number is unitless and there is no range limit.
Positive values represent normalization of tumor metabolism and negative values suggest no improvement or worsening of metabolic character.
|
9 weeks
|
Proportion of Patients Who Experience Metabolic Restoration Between the Responders and Non-responder Groups by MRS Scans
Time Frame: After 1 week
|
Baseline MRS was performed 1-3 days before initiation of treatment.
Follow-up MRS studies were performed at day 7.
A standard quadrature head coil was used to collect MR data.
A responder was defined as stable disease: determined in glioblastoma to be between a 25% volume increase and 50% volume decrease compared to baseline imaging at the therapy initiation at the 2 month follow-up visit.
The spectroscopic restoration index was calculated (ΔN-acetyl aspartate + Δcreatine + Δmyo-inositol - Δcholine - Δ(lactate / lipids)).
|
After 1 week
|
Measurable Change on Magnetic Resonance Spectroscopy Imaging After Vorinostat Administration
Time Frame: 9 weeks
|
Changes in magnetic resonance spectroscopic imaging signal and semiquantitative analysis of inositol, choline, lactate, and N-acetyl aspartate (NAA) signal are measured.
The values for each of these metabolites are normalized to baseline at one and nine weeks.
The values of all the metabolites at one week are added and this is the magnetic resonance spectroscopic index for one week.
This is done again at nine weeks.
The number is unitless and there is no range limit.
Positive values represent normalization of tumor metabolism and negative values suggest no improvement or worsening of metabolic character.
|
9 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change in Metabolite Levels
Time Frame: Baseline to 1 week
|
Baseline MRS was performed 1-3 days before initiation of treatment.
Follow-up MRS studies were performed at day 7.
A standard quadrature head coil was used to collect MR data.
The change of metabolite level in choline (Cho) and N-acetyl aspartate (NAA) were calculated in ratio by (metabolite after treatment / metabolite before treatment - 1).
The reported ratios represent the Cho-to-NAA ratio at day 7 compared with day 0.
|
Baseline to 1 week
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jeffrey Olson, Emory University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Astrocytoma
- Glioma
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Glioblastoma
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Histone Deacetylase Inhibitors
- Temozolomide
- Vorinostat
Other Study ID Numbers
- NCI-2011-02569
- EMORY IRB #00044064 (Other Identifier: Emory University)
- WCI-44064 (Other Identifier: Winship Cancer Institute)
- R21CA141836 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
Clinical Trials on vorinostat
-
Peter MacCallum Cancer Centre, AustraliaGlaxoSmithKline; Merck Sharp & Dohme LLCTerminatedFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone LymphomaAustralia
-
Indiana University School of MedicineBayerCompletedMyelodysplastic Syndromes | Leukemia, Myeloid, Acute | Leukemia, Promyelocytic, AcuteUnited States
-
Armando Santoro, MDTerminatedSmall Cell Lung CancerItaly
-
The Methodist Hospital Research InstituteWithdrawnNon-Hodgkin Lymphoma
-
Merck Sharp & Dohme LLCCompleted
-
Groupe Francophone des MyelodysplasiesMerck Sharp & Dohme LLCTerminated
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)Completed
-
Virginia Commonwealth UniversityWithdrawn
-
National Center for Tumor Diseases, HeidelbergMerck Sharp & Dohme LLC; University Hospital HeidelbergCompleted
-
Fox Chase Cancer CenterNational Comprehensive Cancer NetworkCompletedLocally Advanced Non-small Cell Lung CancerUnited States